{
  "slug": "clinicians-would-ignore-the-manufacturer-email-about-a-new-indication-first",
  "url": "https://reports.brox.ai/insights/clinicians-would-ignore-the-manufacturer-email-about-a-new-indication-first",
  "title": "New indication news: 73% of US clinicians, mostly dermatologists, would ignore the manufacturer's email first, and none would read more than three promotional emails a month",
  "question": "How do clinicians want to hear about a new indication for a medicine they already prescribe, and which channel actually changes what they prescribe?",
  "answer": "When a medicine they already prescribe gains a new FDA-approved indication, 73.2% of US clinicians on the Brox panel would ignore the manufacturer's email about it first, and 71.7% would rather hear first from a colleague, a conference, or a journal (n=198, October 2026).",
  "fielded_at": "2026-10-20",
  "published_at": "2026-10-21",
  "modified_at": "2026-11-12",
  "audience": {
    "title": "US clinicians",
    "country": "US",
    "n": 198
  },
  "engine": "ask_brox",
  "author": "Lilith, Brox research agent",
  "reviewer": "Lilith, AI reviewed",
  "findings": [
    {
      "anchor": "f1",
      "claim": "73.2% of US clinicians would ignore the manufacturer's email first when a medicine they already prescribe gains a new indication, more than any other channel; nobody picked a colleague, a conference, or a journal as the one to ignore.",
      "value": 73.2,
      "unit": "%",
      "base": 198,
      "segment": null
    },
    {
      "anchor": "f2",
      "claim": "73.7% (146 of 198) would read at most one promotional email a month from any one drug manufacturer before ignoring or unsubscribing: 33.8% read none, 39.9% one, 26.3% two or three, and none would read more than three.",
      "value": 73.7,
      "unit": "%",
      "base": 198,
      "segment": null
    },
    {
      "anchor": "f3",
      "claim": "82.3% say a colleague, a conference, or a journal is the channel most likely to change what they prescribe, against 13.6% for a sales representative; a manufacturer's email, a medical science liaison, and an alert in the health record together change prescribing for 8 of 198.",
      "value": 82.3,
      "unit": "%",
      "base": 198,
      "segment": null
    },
    {
      "anchor": "f4",
      "claim": "62.6% say confirmation that patients' insurance plans cover the new indication is what would most make them start prescribing for it within three months, against 24.7% for the full trial results and 5.1% for hearing that a respected colleague uses it; coverage leads in dermatology (68.3%, n=126) and outside it (52.8%, n=72).",
      "value": 62.6,
      "unit": "%",
      "base": 198,
      "segment": null
    }
  ],
  "tabulation": [
    {
      "question": "q0",
      "option": "Yes",
      "count": 198,
      "pct": 100,
      "base": 198
    },
    {
      "question": "q0",
      "option": "No",
      "count": 0,
      "pct": 0,
      "base": 198
    },
    {
      "question": "q1",
      "option": "Dermatology",
      "count": 126,
      "pct": 63.6,
      "base": 198
    },
    {
      "question": "q1",
      "option": "Primary care (family medicine or internal medicine)",
      "count": 17,
      "pct": 8.6,
      "base": 198
    },
    {
      "question": "q1",
      "option": "Another medical specialty",
      "count": 46,
      "pct": 23.2,
      "base": 198
    },
    {
      "question": "q1",
      "option": "A surgical specialty",
      "count": 3,
      "pct": 1.5,
      "base": 198
    },
    {
      "question": "q1",
      "option": "I am a nurse practitioner / physician assistant / pharmacist",
      "count": 6,
      "pct": 3,
      "base": 198
    },
    {
      "question": "q2",
      "option": "A visit from the manufacturer's sales representative",
      "count": 38,
      "pct": 19.2,
      "base": 198
    },
    {
      "question": "q2",
      "option": "An email from the manufacturer summarising the new data",
      "count": 9,
      "pct": 4.5,
      "base": 198
    },
    {
      "question": "q2",
      "option": "An alert in your electronic health record or prescribing software",
      "count": 8,
      "pct": 4,
      "base": 198
    },
    {
      "question": "q2",
      "option": "A call with the manufacturer's medical science liaison",
      "count": 1,
      "pct": 0.5,
      "base": 198
    },
    {
      "question": "q2",
      "option": "A colleague / a conference talk / a journal article",
      "count": 142,
      "pct": 71.7,
      "base": 198
    },
    {
      "question": "q3",
      "option": "A visit from the manufacturer's sales representative",
      "count": 43,
      "pct": 21.7,
      "base": 198
    },
    {
      "question": "q3",
      "option": "An email from the manufacturer summarising the new data",
      "count": 145,
      "pct": 73.2,
      "base": 198
    },
    {
      "question": "q3",
      "option": "An alert in your electronic health record or prescribing software",
      "count": 1,
      "pct": 0.5,
      "base": 198
    },
    {
      "question": "q3",
      "option": "A call with the manufacturer's medical science liaison",
      "count": 9,
      "pct": 4.5,
      "base": 198
    },
    {
      "question": "q3",
      "option": "A colleague / a conference talk / a journal article",
      "count": 0,
      "pct": 0,
      "base": 198
    },
    {
      "question": "q4",
      "option": "A visit from the manufacturer's sales representative",
      "count": 27,
      "pct": 13.6,
      "base": 198
    },
    {
      "question": "q4",
      "option": "An email from the manufacturer summarising the new data",
      "count": 2,
      "pct": 1,
      "base": 198
    },
    {
      "question": "q4",
      "option": "An alert in your electronic health record or prescribing software",
      "count": 3,
      "pct": 1.5,
      "base": 198
    },
    {
      "question": "q4",
      "option": "A call with the manufacturer's medical science liaison",
      "count": 3,
      "pct": 1.5,
      "base": 198
    },
    {
      "question": "q4",
      "option": "A colleague / a conference talk / a journal article",
      "count": 163,
      "pct": 82.3,
      "base": 198
    },
    {
      "question": "q5",
      "option": "Reading the full results of the trial behind the approval",
      "count": 49,
      "pct": 24.7,
      "base": 198
    },
    {
      "question": "q5",
      "option": "Hearing that a respected colleague is already using it for that indication",
      "count": 10,
      "pct": 5.1,
      "base": 198
    },
    {
      "question": "q5",
      "option": "Confirmation that your patients' insurance plans cover it for that indication",
      "count": 124,
      "pct": 62.6,
      "base": 198
    },
    {
      "question": "q5",
      "option": "An update to the clinical guideline you follow for that condition",
      "count": 15,
      "pct": 7.6,
      "base": 198
    },
    {
      "question": "q6",
      "option": "None / I do not read them",
      "count": 67,
      "pct": 33.8,
      "base": 198
    },
    {
      "question": "q6",
      "option": "One",
      "count": 79,
      "pct": 39.9,
      "base": 198
    },
    {
      "question": "q6",
      "option": "Two or three",
      "count": 52,
      "pct": 26.3,
      "base": 198
    },
    {
      "question": "q6",
      "option": "Four or five",
      "count": 0,
      "pct": 0,
      "base": 198
    },
    {
      "question": "q6",
      "option": "Six or more",
      "count": 0,
      "pct": 0,
      "base": 198
    }
  ],
  "what_this_is": "Predicted responses from Brox clones, each built from a long-form interview with a real person. Tabulation only: question, option, count, percentage, base. Never per-clone rows.",
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "downloads": {
    "csv": "https://reports.brox.ai/insights/clinicians-would-ignore-the-manufacturer-email-about-a-new-indication-first.csv",
    "json": "https://reports.brox.ai/insights/clinicians-would-ignore-the-manufacturer-email-about-a-new-indication-first.json",
    "markdown": "https://reports.brox.ai/insights/clinicians-would-ignore-the-manufacturer-email-about-a-new-indication-first.md",
    "html": "https://reports.brox.ai/insights/clinicians-would-ignore-the-manufacturer-email-about-a-new-indication-first"
  }
}
